TERMINATED

Evaluating Emetine for Viral Outbreaks (EVOLVE)

Talk to us

Conditions

COVID-19

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: * Take Emetine 6mg orally for 10 consecutive days * Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms * Undergo blood draws Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.

Official Title

Emetine for Viral Outbreaks: Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate Oral Emetine Against Covid-19 (EVOLVE)

Quick Facts

Study Start:2024-05-15
Study Completion:2025-12-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:TERMINATED

Study ID

NCT05889793

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 30 years of age or older at time of randomization
  2. * RT-PCR positive for SARS-CoV-2 infection within ≤ 10 days of the screening visit.
  3. * In addition to confirmed RT-PCR, symptomatic Covid-19 patients with at least two or more symptoms within 7 days of the screening visit: Cough, shortness of breath, fever/chills, sore throat, nausea, vomiting, diarrhea, fatigue, body aches, headache
  4. * Ability to give informed consent (administered in local language)
  5. * Asymptomatic Covid-19 patients
  6. * Pregnant or breastfeeding woman
  7. * Current or recent use of the study drug
  8. * Known allergy to study drug
  9. * Current or planned participation in another interventional trial in next 10 days.
  10. * Critical Covid-19 patients (ARDS) at the time of screening.
  11. * Patients needing intubation, mechanical ventilation, or ICU care at screening
  12. * Patients with prior cardiac disease including cardiac dysrhythmias, heart failure, ischemic heart disease or cardiomyopathies.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Kunchok Dorjee, MBBS, PhD, MPH
PRINCIPAL_INVESTIGATOR
Johns Hopkins School of Medicine

Study Locations (Sites)

Johns Hopkins University, Division of Infectious Diseases
Baltimore, Maryland, 21231
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Kunchok Dorjee, MBBS, PhD, MPH, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-15
Study Completion Date2025-12-15

Study Record Updates

Study Start Date2024-05-15
Study Completion Date2025-12-15

Terms related to this study

Additional Relevant MeSH Terms

  • COVID-19